AbbVie Inc. (NYSE: ABBV) reported fourth-quarter earnings and revenue that exceeded Wall Street expectations, supported by strong momentum in its immunology and neuroscience franchises, although shares slipped more than 2% in premarket trading following the release.
The pharmaceutical company posted adjusted earnings per share of $2.71 for the quarter, above the consensus estimate of $2.65. Revenue totaled $16.62 billion, topping analyst expectations of $16.39 billion and reflecting reported growth of 10.0% year over year, or 9.5% on an operational basis.
Immunology remained the primary growth engine, with global net revenues climbing 18.3% to $8.63 billion. Skyrizi generated $5.01 billion in sales, up 32.5% from a year earlier, while Rinvoq contributed $2.37 billion, representing growth of 29.5%. These gains more than offset continued erosion in Humira, where sales declined 25.9% to $1.25 billion due to biosimilar competition.
AbbVie’s neuroscience portfolio also delivered strong results, with revenue rising 17.9% to $2.96 billion. Vraylar sales increased 10.5% to $1.02 billion, while Botox Therapeutic revenue advanced 13.4% to $990 million.
The oncology portfolio declined modestly by 1.5% to $1.66 billion, as Imbruvica sales fell 20.8%, partially offset by growth in Venclexta and Elahere.
Looking ahead, AbbVie issued full-year 2026 adjusted earnings guidance of $14.37 to $14.57 per share, above the analyst consensus of $14.22. The outlook excludes any impact from acquired IPR&D and milestone-related expenses.
